Request for Proposals - Independent Medical Education

The grant review process evaluates all grant applications based upon perceived educational need, design, scientific rigor of the proposal and compliance with both industry and argenx independent medical education guidelines.

The approval of a proposal will depend on available funding and alignment with the educational areas of interest as outlined in the argenx IME RFP. All decisions regarding grant proposals are made through a formal, grant review and decision-making process by the argenx independent medical education review committee.

All submitted grant proposals are reviewed regardless of whether they were submitted in response to a current RFP, however, RFP responsive proposals will be prioritized. Should your organization be interested in submitting a proposal, please click on the hyperlink below for the Grants portal to start the process of submission. For any questions, please reach out to [email protected].

Current Open Request for Proposals:

 

Clinical Management of Glucocorticoid Toxicity in Treatment of gMG

argenx supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, and education) to improve patient outcomes in areas of unmet medical need that are aligned with argenx medical and scientific strategies. Through this RFP, it is our intent to support IME programs in the following areas of interest.


Areas of Interest

  • Tools and resources currently available to improve systematic surveillance for glucocorticoid adverse events in the gMG clinical setting (e.g. Metabolic Glucocorticoid Toxicity Index) 
  • Considerations for more effective clinical management of patients given common comorbidities of MG and how known steroid toxicities may contribute to their worsening. 
  • Role of new and emerging non-steroid gMG therapies (e.g. FcRn inhibitors) in the current treatment paradigm to assist clinicians in managing the adverse events of glucocorticoid therapy while improving outcomes for gMG patients. 
  • Quality of life data, health economic data with new gMG treatment, real world data on the impact of FcRn inhibitors in supporting steroid sparing treatment goals.  
  • Considerations for future MG treatment guidelines to include glucocorticoid adverse events surveillance and management.  


Target Audience

  • Minimum CME/CE requirement, 1 credit for all proposals 
  • Educational credits in North America and Europe  
  • MDs, NPs, PAs, PharmD/RPh in neurology, neuromuscular, or neuroimmunology disease space. 


RFP Timeline

  • We will be accepting proposals until November 14th, 2023. Awards will begin to be circulated after November 28th.  


Questions regarding this RFP must be submitted to [email protected]. To access the portal to submit a grant application please register and log into the argenx Grants portal. Thank you for your interest in argenx.

FcRn Inhibition for the Treatment of Myasthenia Gravis – Potential impact on Disease Management Paradigms

argenx supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, and education) to improve patient outcomes in areas of unmet medical need that are aligned with argenx medical and scientific strategies. Through this RFP, it is our intent to support CME/CE programs in the following areas of interest.


Areas of Interest

  • The rationale for targeted immune-mediated therapy in the treatment and management of gMG 
  • Understanding the mechanism of action of FcRn in the context of autoantibody mediated pathophysiology of gMG  
  • A review of recent clinical trial data for FcRn including long-term safety 
  • Potential impact of FcRn inhibitors on current international treatment guidance for gMG (e.g. earlier in disease course, steroid reducing strategies) 
  • Considerations for use of FcRn inhibitor therapy including optimal patient profile and dosing regimen


Program Format Considerations

  • Program to start after January 1st, 2024
  • A single program consisting of up to major neurology medical care centers across the US with preference for live in-person sessions; “Grand Rounds” format preferred
  • Enduring content for at least 12-months after launch of program.


Target Audience

  • Minimum CME/CE requirement, 1 credit for all proposals 
  • Educational credits in North America MDs, NPs, PAs, PharmD/RPh in neurology, neuromuscular, or neuroimmunology disease space.


RFP Timeline

  • We will be accepting proposals for this RFP until November 20th.


Questions regarding this RFP must be submitted to [email protected]. To access the portal to submit a grant application please register and log into the argenx Grants portal. Thank you for your interest in argenx.

argenx grants
Together We Discover